Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently under investigation and ICIs are still looking for their niche in this setting. In this Editorial, we discuss recentl...
Main Authors: | Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-08-01
|
Series: | Cancer Control |
Online Access: | https://doi.org/10.1177/1073274820948047 |
Similar Items
-
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
by: Angela Dalia Ricci, et al.
Published: (2020-10-01) -
PD-L1, TMB, MSI, and Other Predictors of Response toImmune Checkpoint Inhibitors in Biliary Tract Cancer
by: Alessandro Rizzo, et al.
Published: (2021-02-01) -
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
by: Angela Dalia Ricci, et al.
Published: (2020-08-01) -
Immunotherapy in Advanced Biliary Tract Cancers
by: Alice Boilève, et al.
Published: (2021-03-01) -
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
by: Alessandro Rizzo MD, et al.
Published: (2020-12-01)